Physician profile

Brian K Mitchell

Cardiovascular Disease · Norfolk, VA

NPI 1982059754

$4,461.90

in general payments reported to CMS, 2019-2025

30 companies · $2,109 in 2025

The $2,109 reported for 2025 was more than what 84% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$2,321.89
Travel and Lodging$1,476.57
Education$274.99
Grant$271.74

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Abbott Laboratories $2,237.81 2023-2025 Xience Skypoint, Ultreon, Diamondback Coronary
Shockwave Medical, INC $617.09 2024 Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter
Boston Scientific Corporation $271.74 2023
Astrazeneca Pharmaceuticals LP $172.20 2023-2025 Tagrisso, Enhertu
Philips North America LLC $141.44 2024 (Bq9) Coronary Ivus, (Br0) Coronary Atherectomy
Medtronic, INC. $128.21 2023 Telescope
Edwards Lifesciences Corporation $126.76 2024 Edwards Sapien 3 Ultra Transcatheter Heart Valve
Zoll Circulation INC $113.30 2025 Catheter, Downstream Cartridge, Therox Ds2 Console
Genentech USA, INC. $78.29 2022-2025 Tecentriq
Chiesi USA, INC. $72.00 2023 Kengreal
Takeda Pharmaceuticals U.S.A., INC. $56.84 2024 Vpriv
Cook Medical LLC $48.79 2023 Zenith Alpha
Mirati Therapeutics, INC. $46.70 2023 Krazati
Pfizer INC. $29.34 2025
Celltrion USA INC. $26.24 2023 Vegzelma
Show all 30 companies
CompanyGeneral paymentsYearsTop products
Glaxosmithkline, LLC. $25.79 2024 Jemperli, Zejula
Karyopharm Therapeutics INC. $24.84 2024 Xpovio
Canon Medical Systems USA, INC. $23.62 2024 Interventional Angiography System
Stemline Therapeutics INC. $23.44 2023 Orserdu
Jazz Pharmaceuticals INC. $22.48 2023 Zepzelca
Seagen INC. $21.12 2022
Kite Pharma, INC. $20.51 2022
G1 Therapeutics, INC. $20.29 2022
Pharmacosmos Therapeutics INC. $19.93 2024 Monoferric
Daiichi Sankyo INC. $18.77 2024 Injectafer
Emd Serono, INC. $17.60 2025
Servier Pharmaceuticals LLC $17.55 2023
Novocure INC. $17.19 2023
Genmab U.S., INC. $16.62 2024 Epkinly
Zoll Services LLC (A/K/A Zoll Lifecor Corp) $5.40 2025 Lifevest

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Brian K Mitchell

$4,461.90

in general payments reported 2019-2025

Years
2022-2025
Top company
Abbott Laboratories
Context
The $2,109 reported for 2025 was more than what 84% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).

https://glasscript.com/doctor/2790418/brian-k-mitchell

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.